Abstract: Three-dimensional (3D) bioprinting represents a transformative technology in regenerative medicine, enabling the precise fabrication of patient-specific, multicellular tissue constructs and organoids with complex architectures. This additive manufacturing approach leverages biomaterials, living cells, and biologics to replicate functional tissues and organ systems. The bioprinting process encompasses three pivotal stages—preprinting, bioprinting, and post-printing—each governed by advanced imaging, computer-aided design modeling, bioink formulation, and bioreactor-based maturation. Key bioprinting modalities, including extrusion-based, laser-assisted, inkjet-based, and stereolithographic techniques, differ in resolution, cell viability, and scalability but collectively show promise in generating cartilage, skin, bone, esophageal, and tracheal tissues. Natural and synthetic polymers, such as collagen, alginate, gelatin, polycaprolactone, and polylactic acid (PLA), serve as important bioink components, affecting cell adhesion, proliferation, and biocompatibility. Despite considerable progress, clinical translation remains limited by issues such as limited vascularization and innervation, bioink standardization, and ethical, regulatory, and sterility concerns. Successful in vivo transplantation requires the integration of biomimicry, vascular-like networks, and optimized degradation kinetics. Emerging efforts focus on improving resolution, cell density, and regulatory guidance—highlighted by agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure safety and efficacy in clinical applications. This review consolidates advances in bioprinting strategies, materials, and applications, emphasizing the importance of interdisciplinary approaches for functional tissue reconstruction. With continued innovation and standardization, 3D bioprinting has the potential to revolutionize personalized medicine, tissue engineering, transplantation, reduce organ donor dependency, and advance therapeutics through bioprinted constructs tailored for individual patients.
Yadav et al. (Thu,) studied this question.